Patents by Inventor Jörg Wischhusen

Jörg Wischhusen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15)
    Publication number: 20180305447
    Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.
    Type: Application
    Filed: March 12, 2018
    Publication date: October 25, 2018
    Inventors: Jörg WISCHHUSEN, Markus JUNKER, Thomas MÜLLER, Stefan SAREMBA
  • MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR TREATING CANCER CACHEXIA AND CANCER
    Publication number: 20180298091
    Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.
    Type: Application
    Filed: March 5, 2018
    Publication date: October 18, 2018
    Inventors: Jörg WISCHHUSEN, Markus JUNKER, Tina SCHÄFER, Dirk PÜHRINGER
  • GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS
    Publication number: 20180292412
    Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.
    Type: Application
    Filed: September 30, 2016
    Publication date: October 11, 2018
    Inventors: Jörg WISCHHUSEN, Markus HAAKE, Reinhard DUMMER, Matthias MEHLING
  • MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR TREATING CANCER CACHEXIA AND CANCER
    Publication number: 20170204174
    Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 20, 2017
    Inventors: Jörg WISCHHUSEN, Markus JUNKER, Tina SCHÄFER, Dirk PÜHRINGER
  • MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15)
    Publication number: 20150239968
    Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.
    Type: Application
    Filed: September 26, 2013
    Publication date: August 27, 2015
    Inventors: Jörg Wischhusen, Markus Junker, Thomas Müller, Stefan Saremba
  • Method of modulating cellular activity and agents useful for same
    Patent number: 7531575
    Abstract: Described is a rational design of therapeutic and/or prophylactic methods of treating conditions characterized by aberrant or otherwise unwanted microglial cell functioning and rational design methods for treating a range of neurological disorders which are characterized by nitric oxide induced neuronal damage.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: May 12, 2009
    Assignee: Eberhard-Karls-Universität Tübingin
    Inventors: Michael Weller, Wolfgang Wick, Jörg Wischhusen, Michael Platten